Breaking News Instant updates and real-time market news.

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/20/18
02/20
04:55
02/20/18
04:55

American Academy of Dermatology holds annual meeting

2018 AAD Annual Meeting will be held in San Diego, CA on February 16-20.

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

$278.50

(0.00%)

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

$13.76

(0.00%)

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

  • 20

    Feb

  • 21

    Feb

  • 26

    Feb

  • 02

    Mar

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 04

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 07

    Jun

  • 13

    Nov

ACRS Aclaris Therapeutics
$20.13

-0.09 (-0.45%)

09/19/17
CANT
09/19/17
NO CHANGE
Target $50
CANT
Overweight
Public FDA meeting positive for Aclaris, says Cantor
The FDA last Monday conducted a public meeting on alopecia areata patient-focused drug development, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The meeting was constructive on alopecia as a disease and the need to get drugs approved, the analyst contends. She believes the meeting is a positive for Aclaris Therapeutics, which she notes is working on "several solutions to the problem." Chen has an Overweight rating on Aclaris with a $50 price target.
04/26/17
LEER
04/26/17
NO CHANGE
Target $54
LEER
Outperform
Aclaris patent could be worth $15 per share, says Leerink
Leerink analyst Seamus Fernandez believes the A-101 patent announced today by Aclaris Therapeutics could add $15 per share to the company's net present value. The newly allowed patent expires in 2035, 11 years later than the analyst currently assumes loss of exclusivity in seborrheic keratosis. Extending the patent life of A-101 could increase the NPV contribution to $31 per share from $16, Fernandez tells investors in a research note. He keeps an Outperform rating on Aclaris with a $54 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $50
CANT
Overweight
Aclaris Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Aclaris Therapeutics with an Overweight rating and $50 price target.
02/08/18
GUGG
02/08/18
INITIATION
Target $53
GUGG
Buy
Aclaris Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated Aclaris Therapeutics with a Buy and $53 price target.
ABBV AbbVie
$118.60

3.7 (3.22%)

02/15/18
PIPR
02/15/18
NO CHANGE
Target $138
PIPR
Overweight
AbbVie price target raised to $138 from $130 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that after "an unexpected (and somewhat alarming) mid-day trading halt," AbbVie announced its board's approval of a new capital allocation plan, as the company had indicated was in the works. Following the buyback increase and dividend hike, Raymond said the dividend yield rises to an "impressive" 3.5% and he now models the company repurchasing over 105M shares between 2018 and 2020. Given the impact of the buybacks on his EPS estimates, Raymond raised his price target on AbbVie shares to $138 from $130 and he keeps an Overweight rating on the stock.
02/02/18
ARGS
02/02/18
NO CHANGE
Target $145
ARGS
Buy
AbbVie price target raised to $145 from $120 at Argus
Argus analyst David Toung raised his price target on AbbVie to $145 and kept his Buy rating after a "solid" Q4 earnings report that also included a substantial boost from lower tax rates. Toung says AbbVie is likely to submit more applications for new products and expanded indications of existing drugs this year as it develops new growth drivers such as Imbruvica and Mavyret to complement the current large contribution from Humira.
01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.
AGN Allergan
$164.04

-0.43 (-0.26%)

01/29/18
01/29/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Allergan (AGN) upgraded to Overweight from Equal Weight at Barclays with analyst Douglas Tsao saying Allergan's aesthetics franchise is undervalued at current share levels. 2. Halliburton (HAL) upgraded to Neutral from Underweight at Atlantic Equities. 3. Ruth's Hospitality (RUTH) upgraded to Outperform from Market Perform at Raymond James with analyst Brian Vaccaro saying he is optimistic the high end steakhouse category can sustain into 2018 as strong business sentiment and corporate tax cuts bode well for T&E budgets. 4. Unilever (UN, UL) upgraded to Buy from Hold at Investec. 5. Kinder Morgan (KMI) upgraded to Buy from Hold at Argus with analyst Bill Selesky citing the company's "strong recent operational performance," the management's plan for a dividend hike, and attractive valuation in his rating change. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/18
BTIG
01/25/18
NO CHANGE
Target $7
BTIG
Buy
Synergy funding worries may be overdone, says BTIG
BTIG analyst Timothy Chiang noted that Synergy Pharmaceuticals (SGYP) announced that Trulance received expanded FDA approval for IBS-C, which puts it more on par with market leader Linzess from Ironwood (IRWD) and Allergan (AGN). He sees Trulance benefiting from increased payor access and believes the company will have sufficient cash in order to gain access to a second loan tranche of $100M expected by next month, stating that funding worries may be overdone. Chiang keeps a Buy rating and $7 price target on Synergy shares.
01/29/18
LEHM
01/29/18
UPGRADE
Target $230
LEHM
Overweight
Allergan upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Allergan to Overweight and raised his price target for the shares to $230 from $220. The Botox maker closed Friday down 19c to $186.93. Allergan's aesthetics franchise is undervalued at current share levels, Tsao tells investors in a research note. The analyst notes he's been on the sidelines with respect to the stock for three-plus years. Tsao says his firm's survey of 61 plastic surgeons and dermatologists validates Botox's market leader position. Physicians in the survey reported that 67% of Botox patients are "very satisfied" with results, which was well ahead of Dysport and Xeomin at 36% & 20%, respectively, Tsao writes.
ALIOF Actelion
$278.50

(0.00%)

04/19/17
UBSW
04/19/17
NO CHANGE
Target $136
UBSW
Buy
Johnson & Johnson weakness a buying opportunity, says UBS
UBS analyst Matt Miksic believes Johnson & Johnson (JNJ) delivered a solid bottom line beat on in-line sales but prior period adjustments impacted Pharma growth, making the as-reported results look less robust. He raised his estimates to include the Actelion (ALIOF), deal which is expected to close in Q2. Miksic views the initial pullback in the stock as creating a particularly attractive entry point for investors. Miksic reiterated his Buy rating and $136 price target on Johnson & Johnson shares.
03/08/17
JPMS
03/08/17
UPGRADE
JPMS
Overweight
Actelion upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded Actelion (ALIOF) to Overweight citing a "high confidence" that the Johnson & Johnson (JNJ) buyout will complete. The analyst sees 7% potential return by mid-2017.
ARDX Ardelyx
$5.80

-0.2 (-3.33%)

10/12/17
CANT
10/12/17
NO CHANGE
Target $14
CANT
Ardelyx target raised to $14 on T3MPO-2 results at Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein raised her price target for Ardelyx to $14 saying the positive T3MPO-2 results in irritable bowel syndrome with constipation should allow the shares to regain lost ground. The data show a path to new drug application submission and a commercial opportunity above the current valuation, Goldstein tells investors in a research note. She reiterates an Overweight rating on Ardelyx.
10/12/17
10/12/17
NO CHANGE
Target $19

Buy
Ardelyx price target raised to $19 after 'clean win' for tenapanor at Citi
As previously reported, Citi analyst Yigal Nochomovitz raised his price target on Ardelyx to $19 from $14 after the company's phase 3 trial of tenapanor in IBS-C resulted in a "clean win" by not only meeting its composite primary endpoint but also independently meeting both components of the primary endpoint and all secondary endpoints. The analyst raised his U.S. peak sales forecast for tenapanor in IBS-C to $320M from $270M and keeps a Buy rating on the stock, which is up 55% to $8.36 in morning trading.
10/12/17
SBSH
10/12/17
NO CHANGE
Target $19
SBSH
Buy
Ardelyx price target raised to $19 from $14 at Citi
10/17/17
LEER
10/17/17
INITIATION
Target $13
LEER
Outperform
Ardelyx reinitiated with an Outperform at Leerink
Leerink analyst Seamus Fernandez resumed coverage of Ardelyx with an Outperform rating and a $13 price target noting that in the last 9 months, the clinical profile of its lead asset tenapanor has been validated in three Phase 3 studies in two separate indications.
BVX Bovie Medical
$2.50

0.1 (4.17%)

12/18/17
PIPR
12/18/17
NO CHANGE
PIPR
Overweight
Goodwin an 'ideal candidate' to lead Bovie Medical, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien called Charles Goodwin an "ideal candidate" to take over as the new CEO of Bovie Medical. He also noted that although the company lowered its FY17 guidance its advanced energy sales guidance is unchanged, which he sees as important. The analyst, who keeps an Overweight rating on Bovie shares, sees current levels as a good place for long-term investor to start or build positions.
05/16/17
CHLM
05/16/17
NO CHANGE
Target $4.5
CHLM
Buy
Bovie Medical guidance looks achievable, says Craig-Hallum
Craig-Hallum analyst Charles Haff lowered his price target on Bovie Medical to $4.50 from $7 after the company's Q1 revenue and losses were worse than he expected, primarily due to lower than expected J-Plasma sales. However, he notes that management provided annual guidance for the first time and he views their estimates as achievable. Haff keeps a Buy rating on Bovie shares.
12/19/17
CHLM
12/19/17
NO CHANGE
CHLM
Bovie CEO change unexpected, but 'resets expectations,' says Craig-Hallum
Craig-Hallum analyst Matt Hewitt wrote in a research note that while Rob Gershon's resignation as CEO of Bovie Medical on Monday and the subsequent appointment of Charlie Goodwin was a bit "unexpected," some investors had been asking for a change, so the news may be viewed as a positive. Hewitt maintained a Buy rating and $4.50 price target on Bovie Medical shares.
04/13/17
PIPR
04/13/17
NO CHANGE
Target $6
PIPR
Overweight
Piper calls Bovie Medical underappreciated after management meetings
After hosting investor meetings with management, Piper Jaffray analyst Matt O'Brien says Bovie Medical's growth is being underappreciated by investors. The company's J-Plasma technology has the potential to drive "considerable growth" over the next several years, O'Brien tells investors in a research note. He believes "patient investors" should be starting positions at current share levels. The analyst has an Overweight rating on Bovie with a $6 price target.
CELG Celgene
$95.26

-0.88 (-0.92%)

02/09/18
PIPR
02/09/18
NO CHANGE
PIPR
Piper Jaffray reiterates Outperform on Crispr after CSO departure
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $39 price target on Crispr Therapeutics, despite Crispr trading down over 13% on news that Dr. Bill Lundberg is stepping down as Chief Scientific Officer and Celgene (CELG) has reduced its stake in the company to 6.1% from 8.0%. Tenthoff said he remains focused on Crispr's "therapeutic opportunity with first-in-man CTX001 Beta thalassemia and potentially sickle cell disease data this year."
02/13/18
02/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/18
LEHM
02/13/18
UPGRADE
Target $105
LEHM
Overweight
Celgene upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Celgene to Overweight with an unchanged price target of $105. The analyst remains concerned about Revlimid concentration risk long-term, but says the current valuation largely reflects the risk. Since the highs in October 2017, the stock has dropped $55 per share, Meacham tells investors in a research note. He notes Celgene's risk/reward profile based on his net present value analysis yields an "attractive upside case."
01/29/18
WELS
01/29/18
NO CHANGE
Target $23
WELS
Outperform
Iovance Biotherapeutics price target raised to $23 from $17.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.
CUTR Cutera
$48.40

-2.1 (-4.16%)

06/27/17
GABE
06/27/17
NO CHANGE
GABE
Buy
Cutera named a 2H 2017 best idea at Gabelli
Gabelli analyst Jennie Tsai named Cutera saying new leadership in various regions along with a renewed focus to drive sustainable growth make it a second half 2017 best idea. The analyst expects increased revenue through sales force expansion and new products and said recent M&A among laser dermatology companies will provide opportunities to drive sustainable growth and market share. Cutera is Buy rated with a $33 price target.
09/14/17
09/14/17
DOWNGRADE

Hold
Follow-up: Cutera downgraded to Hold from Buy at Maxim
As previously reported, Maxim downgraded Cutera to Hold from Buy with a $33 price target. Analyst Anthony Vendetti changed is view citing valuation and difficult year--over-year comps ahead.
08/08/17
ROTH
08/08/17
NO CHANGE
Target $39
ROTH
Buy
Cutera price target raised to $39 from $32 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for Cutera to $39 from $32 after the company reported a "robust" Q2 beat and raised its full-year revenue and EPS outlook. The analyst reiterates a Buy rating on the shares.
09/12/17
ROTH
09/12/17
NO CHANGE
Target $47
ROTH
Buy
Cutera price target raised to $47 from $41 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for Cutera to $47 from $41 after meeting with management. The analyst came away with a bullish view on the company's "meaningful" future growth opportunity with truSculpt in the large and high-growth body contouring market, an aspect which he believes remains underappreciated. Lewis reiterates a Buy rating on the shares.
HSIC Henry Schein
$69.52

1.14 (1.67%)

02/15/18
JPMS
02/15/18
INITIATION
Target $77
JPMS
Neutral
Henry Schein assumed with a Neutral at JPMorgan
JPMorgan analyst Michael Minchak assumed coverage of Henry Schein (HSIC) with a Neutral rating and $77 price target. The analyst believes the valuation remains high relative to the company's longer-term earnings growth targets as well as other names he covers. Minchak this morning also downgraded Patterson Companies (PDCO) to Underweight.
02/13/18
LEER
02/13/18
NO CHANGE
LEER
Market Perform
FTC suit could result in longer-term margin headwinds for Henry Schein, says Leerink
Leerink analyst David Larsen notes that the FTC announced a lawsuit against Henry Schein (HSIC), Patterson (PDCO), and Benco for antitrust pricing behavior. The analyst views this news as being "very serious," and could result in longer-term margin headwinds and multiple compression for Henry Schein. He reiterates a Market Perform on Henry Schein's shares.
02/13/18
WBLR
02/13/18
NO CHANGE
WBLR
William Blair sees FTC suit pressuring Henry Schein, Patterson shares
The Federal Trade Commission yesterday announced it was filing an antitrust suit against Henry Schein (HSIC), Patterson Companies (PDCO), and Benco, the three largest dental distributors in the United States, William Blair analyst John Kreger tells investors in a research note. The analyst says that while this is not the first time anti-competitive allegations have been made against the companies, the FTC complaint will likely "add credence to the antitrust argument, increase the visibility of the risk, and exacerbate investor concerns about the sustainability of pricing and margins." Kreger believes this could put further pressure on the valuations of Henry Schein and Patterson in the near term, particularly until there is some clear evidence of a spending rebound in dental. He has an Outperform rating on Henry Schein and Market Perform rating on Patterson.
01/04/18
EVER
01/04/18
INITIATION
Target $81
EVER
Outperform
Henry Schein initiated with an Outperform at Evercore ISI
Evercore ISI started Henry Schein with an Outperform rating and $81 price target.
JNJ Johnson & Johnson
$133.15

1.92 (1.46%)

01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.
LLY Eli Lilly
$78.97

0.95 (1.22%)

02/01/18
LEER
02/01/18
NO CHANGE
Target $98
LEER
Market Perform
Eli Lilly selloff an overreaction, says Leerink
Following Q4 results, updated 2018 tax and EPS guidance, Leerink analyst Seamus Fernandez tells investors that the pressure in Eli Lilly's shares was "surprising." The analyst views the move as an "overreaction" by investors, but acknowledges that 2018 poses some legitimate risks for diabetes and animal health franchises which we highlighted in an earlier note. It its "hard to get excited" given competitive headwinds, but valuation downside is limited, he contends. Fernandez reiterates a Market Perform rating on the stock, while raised his price target on the shares to $98 from $95 due to the benefit of tax.
01/29/18
MSCO
01/29/18
INITIATION
Target $57
MSCO
Overweight
Radius Health initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison started Radius Health (RDUS) with an Overweight rating and $57 price target, contending that pricing and convenience offer a path for Radius' Tymlos to take share from market leader Forteo, sold by Eli Lilly (LLY). While Tymlos is launching well, Radius' patch development offers a path to long-term market expansion and elacestrant in breast cancer remains underappreciated by consensus, Harrison added.
01/22/18
01/22/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Neutral from Overweight at Atlantic Equities with analyst James Cordwell citing signs that iPhone demand is beginning to soften and emerging challenges to the smartphone's dominance. 2. General Electric (GE) downgraded to Neutral from Buy at BofA/Merrill with analyst Andrew Obin saying he expects management to lower 2018 guidance when it reports fourth quarter earnings on Wednesday. 3. American Express (AXP) downgraded to Neutral from Buy at Guggenheim with analyst Jeff Cantwell citing CCAR risk in 2018, the fact that its balance sheet is liability-sensitive, and the assumption that the company's provision expense will be significantly higher than expected in fiscal 2018. 4. Eli Lilly (LLY) downgraded to Underperform from Neutral at Credit Suisse with analyst Vamil Divan saying he does not believe Lilly is on track to hit its mid-term guidance of 5% annual sales growth from 2015-2020. 5. Symantec (SYMC) downgraded to Neutral from Outperform at Credit Suisse with analyst Brad Zelnick saying accelerating enterprise expectations do not square with mixed channel sentiment. The analyst also lowered his price target on the shares to $30 from $36. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LMNS Lumenis
$13.76

(0.00%)

MYGN Myriad Genetics
$32.81

-0.57 (-1.71%)

11/02/17
PIPR
11/02/17
NO CHANGE
PIPR
Neutral
Myriad trial hit two important secondary endpoints, says Piper Jaffray
Piper Jaffray analyst William Quirk notes shares of Myriad Genetics are sinking after its key growth asset GeneSight missed the primary endpoint from a large, double blind clinical trial. The study, though, hit two important secondary endpoints that may have a positive impact on longer-term private payer coverage, Quirk tells investors in a research note. The analyst believes the secondary endpoints "may prove to be more important for driving future revenue growth." He keeps a Neutral rating on shares of Myriad Genetics.
01/29/18
GSCO
01/29/18
INITIATION
Target $32
GSCO
Sell
Myriad Genetics initiated with a Sell at Goldman Sachs
Goldman analyst Patrick Donnelly initiated Myriad Genetics with a Sell and $32 price target citing "extended" valuation and excess optimism around GeneSight reimbursement.
11/10/17
JPMS
11/10/17
NO CHANGE
Target $19
JPMS
Underweight
JPMorgan continues to see downside risk in Myriad Genetics
After conducting a survey of high-volume, U.S.-based psychiatrists to get a better sense of the traction GeneSight test is seeing and the longer term market opportunity, JPMorgan analyst Tycho Peterson continues to see risk to the downside in Myriad Genetics shares. Responses overall were mixed, with some indicating GeneSight provides meaningful clinical information while others were cautious on the utility of the test, Peterson tells investors in a research note. The analyst believes the failure of the GeneSight clinical utility study to hit the primary endpoint increases questions on Myriad's ability to gain meaningful incremental reimbursement. He keeps an Underweight rating on the shares with a $19 price target.
12/11/17
PIPR
12/11/17
NO CHANGE
PIPR
Overweight
Piper says CMS coding edits could negatively impact Myriad Genetics
The Centers for Medicare and Medicaid Services made an edit to its procedure guidelines, essentially stating labs should use code 81162, instead of combining 81211 and 81213, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst believes Myriad Genetics bills BRCA tests using the two codes. As such, the edit by CMS could have financial implications for the company as 81162 is paid 21% lower than the combined 81211/81213 rate, Quirk points out. He notes, however, that Myriad management states these coding edits were expected and already factored into guidance. Quirk believes the company's outlook for the second half of 2018 "appears low enough," but he notes that this is the first he's heard about the CMS change. He has a Neutral rating on Myriad with a $29 price target. The stock in morning trading is down 3% to $32.66.
MYL Mylan
$42.14

0.49 (1.18%)

01/18/18
LEER
01/18/18
NO CHANGE
LEER
Hospitals' entrant could add to generic industry headwinds, says Leerink
After the New York Times reported that a number of the U.S.'s largest hospital systems plan to create a non-profit generic drug company to fight high prices and drug shortages, Leerink analyst Ami Fadia said she doesn't expect this to have an immediate significant impact on pricing, but does view the news as a continuation of the pricing headwinds seen over the past few years. While unclear what development stage the new generics company is at, the formation of such a company would add one more occupant in an already crowded space, added Fadia. Companies in the generic drug space include Teva (TEVA), Mylan (MYL), Novartis (NVS), Endo (ENDP) and Impax (IPXL).
02/16/18
JPMS
02/16/18
NO CHANGE
Target $53
JPMS
Overweight
Mylan shares setup for outperformance, says JPMorgan
After evaluating the company's pipeline ahead of the Q4 results later this month, JPMorgan analyst Chris Schott says shares of Mylan are setup for outperformance. The company's pipeline opportunities "substantially de-risk" near- to intermediate-term outlook while Mylan's 2018 earnings per share guidance for greater than $5.40 is "highly achievable" assuming a mid-year generic Advair approval, Schott tells investors in a research note. The analyst views the shares as "highly inexpensive" at current levels and keeps an Overweight rating on the name with a $53 price target.
01/24/18
DBAB
01/24/18
NO CHANGE
Target $50
DBAB
Buy
Mylan target raised to $50 on biosimilar opportunity at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert raise his price target for Mylan to $50 from $48 saying biosimilars could be an important driver of longer-term growth. Mylan has one of the largest biosimilar pipelines in the industry and could launch its first biosimilar in the U.S., pegfilgrastim, this year, Gilbert tells investors in a research note. He keeps a Buy rating on the shares.
01/18/18
CANT
01/18/18
NO CHANGE
CANT
Report of hospital plans for generic drug company 'just noise,' says Cantor
Cantor Fitzgerald analyst Louise Chen said that concerns about hospitals possibly manufacturing their own generic drugs, spurred by a New York Times article discussing the subject, are overdone. Generics companies who responded to the analyst noted that sterile manufacturing is very difficult and drug approvals and plant inspections take time, so any opportunity for hospitals is likely many years away at best, unless they decided to acquire a company, said Chen. The analyst, who said the headlines are "just noise," has Neutral ratings on Endo (ENDP), Mylan (MYL) and Teva (TEVA) and an Overweight rating on Impax (IPXL).
NVS Novartis
$86.91

0.23 (0.27%)

01/25/18
CANT
01/25/18
NO CHANGE
Target $105
CANT
Overweight
Cantor reiterates $105 target on Spark Therapeutics after Novartis deal
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Spark Therapeutics (ONCE) with a $105 price target after the company announced a licensing and supply agreement with Novartis (NVS). The deal further emphasizes the "significant value" of Luxturna's commercial opportunity, Piros tells investors in a research note. He believes the agreement places the drug with a strong commercial partner outside the U.S. while enabling Spark to remain focused on the domestic launch and development pipeline.
02/08/18
RBCM
02/08/18
INITIATION
Target $65
RBCM
Outperform
Spark Therapeutics assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of Spark Therapeutics (ONCE) with an Outperform rating and a price target of $65. MacKay says the FDA approval of Luxturna and "ex-Novartis (NVS) collaboration" helps to de-risk the company's earlier-stage hemophilia and inherited retinal disease assets, calling Spark Therapeutics a "trailblazer in the gene therapy space".
02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
01/25/18
LEER
01/25/18
NO CHANGE
Target $100
LEER
Market Perform
Novartis price target raised to $100 from $93 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Novartis to $100 from $93 following a "strong" quarter and above-consensus 2018 guidance. The analyst reiterates a Market Perform rating on the shares.
PFE Pfizer
$36.26

0.55 (1.54%)

12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
02/16/18
SBSH
02/16/18
NO CHANGE
Target $78
SBSH
Buy
Three developments make Pfizer buying Bristol-Myers more likely, says Citi
Citi analyst Andrew Baum raised his price target for Bristol-Myers Squibb (BMY) to $78 from $72 saying three developments over the last week have increased the probability of a Pfizer (PFE) takeover to near 65% from 50%. Bristol closed yesterday up $3.64, or 5.6%, to $68.98. First, Bristol's revenue potential in non-small cell lung cancer is partly de-risked through Checkmate-227 tumor mutation burden data, Baum tells investors in a research note. Second, the NKTR-214 development collaboration and equity stake in Nektar Therapeutics (NKTR) could materially increase Bristol's Opdivo market share, the analyst adds. And third, he believes Pfizer's immuno-oncology efforts "are looking increasingly suspect." Bristol-Myers is likely Pfizer's last chance to have a meaningful position in the $50B-plus per annum immuno-oncology market, Baum contends. He reiterates a Buy rating on Bristol shares.
01/29/18
RHCO
01/29/18
NO CHANGE
Target $40
RHCO
Hold
Pfizer price target raised to $40 from $33 at SunTrust
SunTrust analyst John Boris raised his price target on Pfizer to $40 and kept his Hold rating ahead of this week's earnings. The analyst attributes the price outlook revision to the positive impact of the tax changes, but notes that "transformative large-scale M&A" is needed to bring about return to "robust" long-term growth.
02/07/18
HCWC
02/07/18
NO CHANGE
Target $31
HCWC
Buy
Achaogen price target raised to $31 from $25 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Achaogen (AKAO) to $31 after the FDA classified the outcome of its Q4 reinspection of Pfizer's (PFE) McPherson, Kansas facility as Voluntary Action Indicated. The news provides a clear regulatory path for approval of plazomicin out of the McPherson facility, Arce tells investors in a research note. He views the outcome as an "important risk-reducing development" that removes an overhang on Achaogen shares. The analyst keeps a Buy rating on the name.
PG Procter & Gamble
$82.60

0.19 (0.23%)

12/13/17
DBAB
12/13/17
INITIATION
Target $101
DBAB
Buy
Procter & Gamble initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Steve Powers started Procter & Gamble with a Buy rating and $101 price target. The company is well positioned after "finally" catching up with market realities," the analyst contends. He views the risk/reward as attractive at current share levels.
01/16/18
01/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Buy from Neutral at Nomura Instinet with analyst Romit Shah saying with Broadcom's (AVGO) hostile takeover attempt now analogous to a "gun to the head," Qualcomm management is likely to more aggressively focus on driving shareholder value in order to remain a standalone franchise. 2. Twitter (TWTR) upgraded to Buy from Sell at Aegis with analyst Victor Anthony saying he believes 2018 will be an inflection point in owned and operated advertising for Twitter and he sees a return to double-digit growth in that area in 2019. 3. Procter & Gamble (PG) upgraded to Neutral from Sell at Goldman Sachs with analyst Jason English saying he no longer sees enough downside to estimates to drive material underperformance for the stock. 4. Northrop Grumman (NOC) and Curtiss-Wright (CW) were upgraded to Outperform from Market Perform at Wells Fargo. 5. Ciena (CIEN) was upgraded to Buy from Neutral at Goldman Sachs, while Adtran (ADTN) was upgraded to Neutral from Sell. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/27/17
JEFF
12/27/17
NO CHANGE
JEFF
Nielsen shows improved two-week sales trends, says Jefferies
Jefferies analyst Kevin Grundy says two-week sales growth in U.S. Nielsen channels improved sequentially for key home and personal care companies Colgate-Palmolive (CL), Church & Dwight (CHD) and Clorox (CLX), as well as beverage companies Monster Beverage (MNST), Coca-Cola (KO) and Dr Pepper Snapple (DPS). While overall growth remains tepid, sequential improvement in December for consumer spending, including staples, has been more upbeat, Grundy tells investors in a research note titled "Party Like It's 1999? Not Quite, But US Nielsen HPC/Bevs 2-Week Data Improves." The analyst favors shares of Church & Dwight, Procter & Gamble (PG), Dr Pepper and Monster.
01/16/18
GSCO
01/16/18
UPGRADE
Target $88
GSCO
Neutral
Procter & Gamble upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jason English upgraded Procter & Gamble to Neutral and raised his price target for the shares to $88 from $83. The analyst no longer sees enough downside to estimates to drive material underperformance for the stock. he admits his expectation of a negative estimate revision cycle has failed to materialize.
PRGO Perrigo
$89.55

-0.1 (-0.11%)

02/01/18
BREN
02/01/18
INITIATION
Target $117
BREN
Buy
Perrigo initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Perrigo with a Buy and $117 price target.
12/22/17
CANT
12/22/17
NO CHANGE
CANT
Cantor ups price targets for Teva, Valeant, Mylan, Zoetis
Cantor Fitzgerald analyst Louise Chen raised her price target for Neutral-rated Teva (TEVA) to $18 from $10, for Overweight-rated Valeant (VRX) to $25 from $23, for Neutral-Mylan (MYL) to $41 from $34 and for Overweight-rated Zoetis (ZTS) to $85 from $80. Heading into 2018, the analyst believes Perrigo (PRGO) has the best setup in the Specialty Pharmaceuticals space. The company has given the most visibility on its outlook for 2018, Chen tells investors in a research note. She believes Zoetis, Mylan and Horizon Pharma (HZNP) also look good into next year.
01/04/18
DBAB
01/04/18
NO CHANGE
Target $97
DBAB
Buy
Amazon now selling products sourced by Perrigo, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert says that in recent months, Amazon (AMZN) has begun to sell a number of over-the-counter healthcare products, sourced by Perrigo (PRGO), under a brand called "Basic Care." The price per unit to the consumer tends to be similar to Walmart's (WMT) pricing and generally below that of some other retailers, Gilbert tells investors in a research note, citing his own analysis. He believes Amazon, at least for now, is not going out of its way to position the Basic Care brand on the site in a preferential way. Further, the analyst does not expect Perrigo to "play up" this development as Amazon is, for now, just a small customer and the company likely won't want to "rock the boat unnecessarily with its larger customers." Gilbert also assumes that Perrigo is not offering better prices to Amazon than it would to other customers. The analyst does not see much potential for near and medium term upside for Perrigo tied to its arrangement with Amazon. Gilbert keeps a Buy rating on the shares with a $97 price target. The stock in premarket trading is down 50c to $88.94.
01/02/18
LEER
01/02/18
INITIATION
Target $90
LEER
Market Perform
Perrigo initiated with a Market Perform at Leerink
Leerink analyst Ami Fadia initiated Perrigo with a Market Perform and $90 price target.
REGN Regeneron
$332.15

-1.03 (-0.31%)

02/09/18
02/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Sector Perform from Underperform at RBC Capital with analyst Mark Mahaney saying the fourth quarter revenue and EBITDA were materially better than expected, and while MAU's were below consensus, DAU's grew for the first time at a double-digit rate. 2. iRobot (IRBT) upgraded to Outperform from Market Perform at Raymond James with analyst Mark Strouse saying he sees a more balanced risk/reward following the recent pullback in the shares. 3. Regeneron (REGN) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney noting its selloff since last year and believes its valuation has reached a point where the selloff is overdone. 4. Teva (TEVA) upgraded to Sector Perform from Underperform at RBC Capital with analyst Randall Stanicky saying the 11% sell-off in the stock price following the company's guidance update has removed the debate around 2018 EBITDA target and sees limited downside from the current levels. 5. United Technologies (UTX) upgraded to Buy from Hold at Argus with analyst John Eade saying the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/19/18
JEFF
02/19/18
NO CHANGE
Target $145
JEFF
Buy
AnaptysBio price target raised to $145 from $101 at Jefferies
Jefferies analyst Biren Amin raised his price target for AnaptysBio (ANAB) to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients. The shares closed Friday up $6.59, of 5.5%, to $126.45. Sustained efficacy on a single dose of '020 was seen up to day 78 at EASI-50 in 75% of patients, comparable to Phase II data from Sanofi (SNY) and Regeneron (REGN) competitor Dupixent, Amin tells investors in a research note. ANB020 beats if you account for single dose versus Q2 weeks of Dupi, the analyst contends. He keeps a Buy rating on AnaptysBio.
02/11/18
PIPR
02/11/18
NO CHANGE
Target $494
PIPR
Overweight
Piper Jaffray remains a buyer of Regeneron after Roche data
Piper Jaffray analyst Christopher Raymond remains a buyer of Regeneron (REGN) shares after Phase 2 data from Roche's (RHHBY) VEGF/Ang2 bispecific RG7716 in diabetic macular edema. While RG7716 demonstrated stag-sig BCVA gains compared to Lucentis at week 24 in DME patients previously untreated with anti-VEGF therapies, key questions on safety and efficacy remain unanswered, he contends. Given this, the analyst thinks Regeneron's Eylea remains well-positioned in the DME space. Raymond reiterates an Overweight rating and $494 price target on Regeneron's shares.
SNY Sanofi
$39.91

0.19 (0.48%)

01/24/18
FBCO
01/24/18
NO CHANGE
Target $105
FBCO
Neutral
Bioverativ price target raised to $105 from $65 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Bioverativ (BIVV) to $105 from $65 ahead of likely closing of the Sanofi (SNY) deal. The analyst reiterates a Neutral rating on Bioverativ's shares.
01/24/18
ARGS
01/24/18
DOWNGRADE
ARGS
Hold
Bioverativ downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Bioverativ (BIVV) to Hold from Buy after the company announced a deal to be acquired by Sanofi (SNY) for $105 per share in cash. Hellweg says the strong run-up in the stock and the forthcoming acquisition have fully valued the stock at current levels.
02/08/18
BERN
02/08/18
NO CHANGE
Target $45
BERN
Market Perform
Sanofi price target lowered to $45 from $50 at Bernstein
Bernstein analyst Tim Anderson lowered his price target for Sanofi to $45 from $50 following a "weak" quarter. The analyst reiterates a Market Perform rating on the shares.
UL Unilever; also tag UN
$53.55

-0.22 (-0.41%)

11/17/17
11/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boardwalk Pipeline (BWP) initiated with a Sell at Goldman Sachs. 2. Ollie's Bargain Outlet (OLLI) initiated with a Sell at Citi. 3. AMN Healthcare (AMN) initiated with an Overweight at KeyBanc. 4. Unilever (UL, UN) initiated with a Hold at Argus. 5. Canada Goose (GOOS) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/18
INVC
01/29/18
UPGRADE
INVC
Buy
Unilever upgraded to Buy from Hold at Investec
02/02/18
ABNA
02/02/18
UPGRADE
ABNA
Hold
Unilever upgraded to Hold from Sell at ABN Amro
UN Unilever; also tag UL
$54.59

-0.15 (-0.27%)

WTKWY Wolters Kluwer
$49.37

-0.27 (-0.54%)

03/10/17
GSCO
03/10/17
UPGRADE
GSCO
Neutral
Wolters Kluwer upgraded to Neutral from Sell at Goldman

TODAY'S FREE FLY STORIES

CZZ

Cosan

$8.32

0.105 (1.28%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Downgrade
Cosan rating change  »

Cosan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

, CYH

Community Health

$2.72

-0.055 (-1.99%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Recommendations
LifePoint, Community Health, Apollo Global, HCA Healthcare analyst commentary  »

Deal activity could pick…

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

CYH

Community Health

$2.72

-0.055 (-1.99%)

APO

Apollo Global

$35.39

-0.22 (-0.62%)

HCA

HCA Healthcare

$108.01

0.31 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 27

    Jul

  • 27

    Jul

  • 02

    Aug

  • 22

    Aug

BIDU

Baidu

$260.00

-2.32 (-0.88%)

09:31
07/23/18
07/23
09:31
07/23/18
09:31
Downgrade
Baidu rating change  »

Baidu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

SLM

Sallie Mae

$11.71

-0.11 (-0.93%)

, CHGG

Chegg

$29.07

-0.07 (-0.24%)

09:31
07/23/18
07/23
09:31
07/23/18
09:31
Hot Stocks
Sallie Mae, Chegg introduce enhanced Study Starter benefit »

Sallie Mae (SLM) and…

SLM

Sallie Mae

$11.71

-0.11 (-0.93%)

CHGG

Chegg

$29.07

-0.07 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

09:30
07/23/18
07/23
09:30
07/23/18
09:30
Hot Stocks
Trump calls U.S. Post Office Amazon's 'delivery boy' at fraction of cost »

President Trump tweeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

HAL

Halliburton

$45.23

0.26 (0.58%)

09:29
07/23/18
07/23
09:29
07/23/18
09:29
Hot Stocks
Halliburton says sees international business better in 2H18 »

Says seeing ramp up in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BV

BrightView

$21.95

0.14 (0.64%)

09:29
07/23/18
07/23
09:29
07/23/18
09:29
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:28
07/23/18
07/23
09:28
07/23/18
09:28
Hot Stocks
Halliburton says sees Q3 effective tax rate approximately 20% »

Says expects go generate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BSX

Boston Scientific

$33.77

0.06 (0.18%)

, SYK

Stryker

$174.33

1.44 (0.83%)

09:26
07/23/18
07/23
09:26
07/23/18
09:26
Recommendations
Boston Scientific, Stryker analyst commentary  »

Boston Scientific price…

BSX

Boston Scientific

$33.77

0.06 (0.18%)

SYK

Stryker

$174.33

1.44 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 14

    Aug

  • 15

    Aug

HAS

Hasbro

$94.02

0.38 (0.41%)

09:26
07/23/18
07/23
09:26
07/23/18
09:26
Hot Stocks
Hasbro says 30% of manufacturing is outside of China »

Says biggest percentage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BV

BrightView

$21.95

0.14 (0.64%)

09:23
07/23/18
07/23
09:23
07/23/18
09:23
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

09:22
07/23/18
07/23
09:22
07/23/18
09:22
Periodicals
VW board member wary of 'humiliating' Audi's Stadler, FT reports »

Hiltrud Werner, a top…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$33.77

0.06 (0.18%)

09:21
07/23/18
07/23
09:21
07/23/18
09:21
Recommendations
Boston Scientific analyst commentary  »

Boston Scientific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 14

    Aug

  • 15

    Aug

HAL

Halliburton

$45.23

0.26 (0.58%)

09:21
07/23/18
07/23
09:21
07/23/18
09:21
Earnings
Halliburton says sees Q3 earnings 'similar' to Q2 »

Says temporary challenges…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

09:20
07/23/18
07/23
09:20
07/23/18
09:20
General news
U.S. Sentiment Strength Extends into July: »

U.S. Sentiment Strength…

MU

Micron

$55.01

-1.2 (-2.13%)

, QCOM

Qualcomm

$58.62

-0.7 (-1.18%)

09:19
07/23/18
07/23
09:19
07/23/18
09:19
Recommendations
Micron, Qualcomm, AMD, Intel, Nvidia, Microchip, Texas Instruments, Marvell, Analog Devices, Cypress Semiconductor analyst commentary  »

Tariff uncertainty a…

MU

Micron

$55.01

-1.2 (-2.13%)

QCOM

Qualcomm

$58.62

-0.7 (-1.18%)

AMD

AMD

$16.49

-0.22 (-1.32%)

INTC

Intel

$51.92

-0.09 (-0.17%)

NVDA

Nvidia

$250.87

-1.15 (-0.46%)

MCHP

Microchip

$94.39

-0.46 (-0.48%)

TXN

Texas Instruments

$114.99

0.34 (0.30%)

MRVL

Marvell

$21.85

0.14 (0.64%)

ADI

Analog Devices

$97.81

-0.46 (-0.47%)

CY

Cypress Semiconductor

$17.06

-0.09 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 07

    Aug

  • 14

    Aug

  • 16

    Aug

HAL

Halliburton

$45.23

0.26 (0.58%)

09:18
07/23/18
07/23
09:18
07/23/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

HAL

Halliburton

$45.23

0.26 (0.58%)

09:18
07/23/18
07/23
09:18
07/23/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
07/23/18
07/23
09:18
07/23/18
09:18
Options
Overnight activity included 89 trades in SPX and 3 trades in VIX »

89 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:17
07/23/18
07/23
09:17
07/23/18
09:17
Hot Stocks
Halliburton says expects international markets to improve in coming quarters »

Says "better…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

MSFT

Microsoft

$106.29

1.59 (1.52%)

09:16
07/23/18
07/23
09:16
07/23/18
09:16
Conference/Events
Microsoft to hold a summit »

Microsoft Business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

HAL

Halliburton

$45.23

0.26 (0.58%)

09:13
07/23/18
07/23
09:13
07/23/18
09:13
Hot Stocks
Halliburton says activity improved in all geographic markets in Q2 »

Says mindful of of impact…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

09:13
07/23/18
07/23
09:13
07/23/18
09:13
General news
Trump is 'very happy,' says 'Japan is happy, all of Asia is happy' »

President Trump just…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMP

Adamis Pharmaceuticals

$3.80

0.125 (3.40%)

09:11
07/23/18
07/23
09:11
07/23/18
09:11
Hot Stocks
Adamis Pharmaceuticals adds sublingual ED product candidate to pipeline »

Adamis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.